Literature DB >> 9571148

In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene.

T Ohnishi1, T Taki, S Hiraga, N Arita, T Morita.   

Abstract

The mammalian RAD51 gene is a homologue of the yeast RAD51 and E. coli RecA genes, which are related to the repair of DNA double-strand breaks and are also involved in recombination repair and various SOS responses to DNA damage by gamma-irradiation and alkylating reagents. In this study, we investigated both in vitro and in vivo whether inhibition of the RAD51 gene by antisense oligonucleotides (ODNs) enhances the radiosensitivity of mouse malignant gliomas. A volume of 100 nM of RAD51 antisense ODNs inhibited the level of mRNA by more than 95% and reduced the protein expression by about 70%. Treatment of mouse 203G glioma cells with 100 nM of RAD51 antisense ODNs significantly enhanced the radiation-induced cell kill compared to control cells, and cells treated with sense or scrambled ODNs. When the glioma cells were implanted in the cisterna magna of mice followed by treatment with RAD51 antisense ODNs, the survival time of the mice was markedly prolonged compared to that of the untreated group (p < 0.001, logrank test). In addition, the combination of antisense ODNs and irradiation extended the survival time of the glioma-bearing mice much longer than could be achieved with radiation alone (p < 0.0001, logrank test). These results suggest that inhibition of RAD51 can be expected to serve as a novel potentiator for radiation therapy in malignant gliomas by inhibiting DNA double-strand break repair.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571148     DOI: 10.1006/bbrc.1998.8440

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells.

Authors:  Li-Qing Du; Xiao-Qing Du; Jian-Qiang Bai; Yan Wang; Qing-Shan Yang; Xiao-Chun Wang; Peng Zhao; Hong Wang; Qiang Liu; Fei-Yue Fan
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

2.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  DNA repair after irradiation in glioma cells and normal human astrocytes.

Authors:  Susan C Short; Christine Martindale; Sara Bourne; Geoff Brand; Mick Woodcock; Peter Johnston
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

Review 4.  Targeting the homologous recombination pathway by small molecule modulators.

Authors:  Fei Huang; Alexander V Mazin
Journal:  Bioorg Med Chem Lett       Date:  2014-05-06       Impact factor: 2.823

5.  DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.

Authors:  Zhiyong Mao; Ying Jiang; Xiang Liu; Andrei Seluanov; Vera Gorbunova
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

6.  FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.

Authors:  Nu Zhang; Xinjian Wu; Lixuan Yang; Feizhe Xiao; Heng Zhang; Aidong Zhou; Zhengsong Huang; Suyun Huang
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

7.  Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.

Authors:  S J Collis; A Tighe; S D Scott; S A Roberts; J H Hendry; G P Margison
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

8.  Polymorphism within the distal RAD51 gene promoter is associated with colorectal cancer in a Polish population.

Authors:  Bartosz Mucha; Jacek Kabzinski; Adam Dziki; Karolina Przybylowska-Sygut; Andrzej Sygut; Ireneusz Majsterek; Lukasz Dziki
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide.

Authors:  Julian Nomme; Axelle Renodon-Cornière; Yuya Asanomi; Kazuyasu Sakaguchi; Alicja Z Stasiak; Andrzej Stasiak; Bengt Norden; Vinh Tran; Masayuki Takahashi
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

10.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.